Evidence map›Paper›PMID 38295025›Full record

ReviewACS infectious diseases2024

Unlocking Opportunities for

Mousumi Shyam, Sumit Kumar, Vinayak Singh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Assessment of TB47 as a potential novel therapeutic agent:Antimicrobial agents and chemotherapy · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mousumi ShyamDepartment of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mersa, Ranchi, Jharkhand 835215, India.ORCID 0000-0002-0791-3772
Sumit KumarHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0002-4588-7237
Vinayak SinghHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0001-9002-2489

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the recent decade, scientific communities have toiled to tackle the emerging burden of drug-resistant tuberculosis (DR-TB) and rapidly growing opportunistic nontuberculous mycobacteria (NTM). Among these, two neglected mycobacteria species of the Acinetobacter family,

Indexed as

Buruli UlcerMycobacteriumMycobacterium ulceransHumansMycobacterium leprae3M mechanismsantitubercularsBuruli ulcerdrug repurposingefflux pump inhibitorsleprosyMycobacterium lepraeMycobacterium ulceransmycolactone analoguesmycolactone biosynthesisPKS inhibitors

Identifiers

PMID38295025
PMCPMC10862552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.